Brimonidine Tartrate

• CAT Number: A000158
• CAS Number: 70359-46-5
• Molecular Formula: C15H16BrN5O6
• Molecular Weight: 442.22
• Purity: ≥95%
• Synonyms: BRIMONIDINE TARTRATE; 70359-46-5; Brimonidine tartarate; Brominide tartrate; Alphagan; Brimonidine D-tartrate
• Target: Adrenergic Receptor Agonist
• Storage: -20°C
• IUPAC Name: 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine;(2R,3R)-2,3-dihydroxybutanedioic acid
• InChI: InChI=1S/C11H10BrN5.C4H6O6/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8;5-1(3(7)8)2(6)4(9)10/h1-4H,5-6H2,(H2,15,16,17);1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1
• InChIKey: QZHBYNSSDLTCRG-LREBCSMRSA-N
• SMILES: C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br.C(C(C(=O)O)O)(C(=O)O)O

Brimonidine Tartrate（Cat No.:A000158）is an alpha-2 adrenergic receptor agonist used primarily to treat open-angle glaucoma and ocular hypertension. By decreasing aqueous humor production and increasing uveoscleral outflow, it effectively lowers intraocular pressure. Additionally, Brimonidine Tartrate is used in topical formulations to reduce facial redness in conditions like rosacea. Its dual action and targeted mechanism make it a valuable medication in ophthalmology and dermatology. The drug’s efficacy and safety profile ensure its continued use in managing chronic eye conditions and certain dermatological issues.

Overview of Clinical Research

Originator: Pfizer
Developer: AbbVie; Allergan; Senju Pharmaceutical
Class: Antiglaucomas; Antihypertensives; Eye disorder therapies; Imidazoles; Quinoxalines; Skin disorder therapies; Small molecules
Mechanism of Action: Alpha 2 adrenergic receptor agonists
Orphan Drug Status: No
New Molecular Entity: Yes